ORLANDO, Fla., Nov. 16, 2011 (GLOBE NEWSWIRE) -- Higher doses of clopidogrel were more effective than standard dosing in patients with a gene variant that blocks some of the drug’s anti-clotting effect, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2011.
